Nasdaq

Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis

HAMILTON, Bermuda, July 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and ...
CNN

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)

Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy endpoint: Hazard Ratio = 0.04, p<0.0001) Safety results consistent with FDA-approved label ...
Pharmabiz

US FDA grants orphan drug status to Kiniksa Pharma’s rilonacept to treat pericarditis

Kiniksa Pharmaceuticals, a biopharmaceutical company, announced that the US Food and Drug Administration (FDA) granted Orphan Drug designation for rilonacept for the treatment of pericarditis, which ...
Nasdaq

Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis

HAMILTON, Bermuda, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological ...